Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 196-204

  Cabibbo, G ^a   Genco, C ^a   Di Marco, V ^a   Barbara, M ^a   Enea, M ^a   Parisi, P ^a   Brancatelli, G ^a   Romano, P ^a   Craxi A ^a   Camma C ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; SORAFENIB;

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DEPENDENT VARIABLE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; SEX RATIO; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959372785     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04694.x     Document Type: Article

References (29)

1. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. (Pubitemid 36152543)
2. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54. (Pubitemid 34680374)
3. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)
4. Llovet JM, Real MI, Montaña X, et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9. (Pubitemid 34607087)
5. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83.
6. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-20.
7. Cammà C, Di Marco V, Orlando A, et al. Unità Interdipartimentale Neoplasie Epatiche (U.I.N.E) Group. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 2005; 42: 535-40. (Pubitemid 40342933)
8. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25. (Pubitemid 44900485)
9. Piscaglia F, Bolondi L,. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? Dig Liver Dis 2010; 42 (Suppl. 3): S258-63.
10. Cammà C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 62-75. (Pubitemid 351782806)
11. Tandon P, Garcia-Tsao G,. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-10.
12. Cammà C, Cabibbo G,. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int 2009; 29: 478-80.
13. Bruix J, Sherman M, Llovet JM, et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30. (Pubitemid 32844200)
14. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
15. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
16. Cox DR,. Regression models and life-tables (with Discussion). JR Stat Soc 1972; 34: 187-220.
17. Therneau T, Grambsch P,. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag, 2000.
18. Heagerty PJ, Zheng Y,. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61: 92-105. (Pubitemid 40380968)
19. Wilcoxon F,. Individual comparisons by ranking methods. Biometr Bull 1945; 1: 80-3.
20. Bauer DF,. Constructing confidence sets using rank statistics. J Am Stat Assoc 1972; 67: 687-90.
21. Testa R, Testa E, Giannini E, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 17: 1563-9. (Pubitemid 36831449)
22. Orlandi F, Christensen E,. A consensus conference on prognostic studies in hepatology. J Hepatol 1999; 30: 171-2. (Pubitemid 29023668)
23. Takayasu K, Arii S, Ikai I, et al. Liver cancer study group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9. (Pubitemid 44142456)
24. Varela M, Sala M, Llovet JM, Bruix J,. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 98-102. (Pubitemid 36831466)
25. Giannini EG, Bodini G, Corbo M, et al. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 493-501.
26. Sala M, Llovet JM, Vilana R, et al. Barcelona clínic liver cancer group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-60. (Pubitemid 39657009)
27. Olivo M, Valenza F, Buccellato A, et al. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis 2010; 42: 515-9.
28. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.
29. Llovet JM, Bruix J,. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.